Adenosine A2A receptor Inhibitors
2 drugsAbout Adenosine A2A receptor
The Adenosine A2A receptor is a G protein-coupled receptor activated by adenosine, a naturally occurring nucleoside. It plays a role in various physiological processes, making it relevant to multiple therapeutic areas.
Currently, there is no genetic evidence directly linking the A2A receptor to specific diseases. However, the existence of approved drugs suggests therapeutic potential.
Two FDA-approved drugs target the A2A receptor: LEXISCAN and NOURIANZ. Both are small molecules, with applications in cardiac stress testing and Parkinson's disease, respectively.
Top Adenosine A2A receptor Drugs
ASTELLAS and KYOWA KIRIN are the companies with approved drugs.
The market is concentrated; new entrants may face challenges in gaining market share.
Adenosine A2A receptor Drug Modality Landscape
Modalities
Routes of Administration
Adenosine A2A receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could create differentiation.
Adenosine A2A receptor Clinical Trials 46 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Adenosine A2A receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 9 | 1 | 4 | 90% |
| Phase 2 | 10 | 6 | 3 | 1 | 67% |
| Phase 3 | 8 | 8 | 0 | 0 | 100% |
| Phase 4 | 14 | 12 | 1 | 1 | 92% |
Top Sponsors
By Modality
Top Conditions
Adenosine A2A receptor Drug Approval Timeline (2008 - 2019)
The first drug was approved in 2008, and the most recent in 2019, spanning 12 years.
The approval timeline suggests moderate interest; further innovation could revitalize the field.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Adenosine A2A receptor. A trial counts if an approved drug acting on Adenosine A2A receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.